Current Science

Open Access Open Access  Restricted Access Subscription Access

A Decade of OSDD for TB:Role and Outcomes


Affiliations
1 CSIR-Institute of Genomics and Integrative Biology (IGIB), New Delhi 110 025, India
2 Academy of Scientific and Innovative Research (AcSIR), New Delhi 110 025, India
 

In this article we estimate the economic benefit of open source drug discovery (OSDD) programme for its decade-long effort of developing newer and novel therapeutics for TB by streamlining the upstream research and development (R&D) of the drug discovery pipeline. The OSDD programme, presently subsumed into the India TB Research and Development Consortium (ITRDC) project led by ICMR, has opened up a novel method of asset utilization and capacity building at a negligible cost, leading to positive economic impact. The OSDD programme has also become an instrumental part of shaping the National Intellectual Property Rights (NIPR) Policy, 2016. This calls for a policy directive as programmes such as OSDD can be a powerful strategy in dealing with the excruciating disease burden of TB and other neglected diseases that countries such as India are facing.

Keywords

Drug Discovery, Economic Benefit, ITRDC, India NIPR, Open Source Drug Discovery, Tuberculosis.
User
Notifications
Font Size

  • Fenwick, A., The global burden of neglected tropical diseases. Public Health, 2012, 126(3), 233–236.

  • Organization, W. H., Investing to Overcome the Global Impact of Neglected Tropical Diseases: Third WHO Report on Neglected Tropical Diseases, World Health Organization, 2015, vol. 3.

  • Hotez, P. J. et al., The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLOS Negl. Trop. Dis., 2014, 8(7), e2865.

  • UNDP, Humanity Divided: Confronting Inequality in Developing Countries, UNDP New York, eNY NY, 2013.

  • Gething, P. and Hay, S., Nations within a Nation: Variations in Epidemiological Rransition Across the States of India, 1990–2016 in the Global Burden of Disease Study, 2017.

  • Maurer, S. M., Rai, A. and Sali, A., Finding cures for tropical diseases: is open source an answer? PLOS Med., 2004, 1(3), e56.

  • Moran, M., Global funding of new products for neglected tropical diseases. In Causes and Impacts of Neglected Tropical and Zoonotic Diseases: Opportunities for Integrated Intervention Strategies: Workshop Summary, National Academies Press, Washington DC, USA, 2011.

  • Von Philipsborn, P. et al., Poverty-related and neglected diseases – an economic and epidemiological analysis of poverty relatedness and neglect in research and development. Glob. Health Action, 2015, 8(1), 25818.

  • Pharma, E., World Preview 2018, Dostupnona, 2011; http://www.evaluategroup.com/Public/EvaluatePharma-World-Preview-2018Embracing-the-Patent-Cliff.aspx (30 June 2013).

  • Zumla, A. I. et al., New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect. Dis., 2014, 14(4), 327–340.

  • Croft, S. L., Neglected tropical diseases in the genomics era: re-evaluating the impact of new drugs and mass drug administration. Genome Biol., 2016, 17(1), 46.

  • Paul, S. M. et al., How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Rev. Drug Discov., 2010, 9(3), 203.

  • Pisano, G. P., Science Business: The Promise, the Reality and the Future of Biotech, Harvard Business Press, 2006.

  • Initiative, O. S., Open Source Definition, 2005.

  • Williams, S., Free as in Freedom (Paperback): Richard Stallman’s Crusade for Free Software, O’Reilly Media, Inc, 2011.

  • DiBona, C., Stone, M. and Cooper, D., Open Sources 2.0: The Continuing Evolution, O’Reilly Media, Inc, 2005.

  • Weber, S., The Success of Open Source, Harvard University Press, 2004.

  • Russell, J., Supercomputer Sales Drove 2016 HPC Market Up to Record $11.2 Billion, 2017; https://www.hpcwire.com/2017/04/06/supercomputer-sales-drove-2016-hpc-market-record-11-2-billion/

  • Nielsen, M., Reinventing Discovery: the New Era of Networked Science, Princeton University Press, 2012.

  • DeLano, W. L., The case for open-source software in drug discovery. Drug Discov. Today, 2005, 10(3), 213–217.

  • Munos, B., Can open-source R&D reinvigorate drug research? Nature Rev. Drug Discov., 2006, 5(9), 723.

  • Masum, H. and Harris, R., Open Source for Neglected Diseases: Magic bullet or Mirage, Results for Development Institute, 2011.

  • So, A. D. and Woodhouse, W., Innovation Tackling Antibiotic Resistance Open Source Drug Discovery Initiative in India, Medicine in health systems: Advancing access, affordability and appropirate use. Alliance for Health Policy and Systems Research, World Health Organization, Geneva, 2014, 1st edn, p. 6.

  • Bigdeli, M., Peters, D. and Wagner, A., Medicines in Health Systems, World Health Organization, Geneva, 2014.

  • Koshy, J., CSIR to Unveil Gene Map for TB on Portal Developed by Infosys, in LiveMint, 2010.

  • Singh, S., I Have to Empower the Youth in the CSIR System, in LiveMint, 2008.

  • Bhardwaj, A., Scaria, V. and Patra, D., Open source drug discovery: A global collaborative drug discovery model for tuberculosis. Sci. Cult., 2011, 1, 22–26.

  • C-DAC. Open Source Drug Discovery, 2017; http://www.garudaindia.in/html/osdd.aspx

  • Bhardwaj, A. et al., Open source drug discovery – a new paradigm of collaborative research in tuberculosis drug development. Tuberculosis, 2011, 91(5), 479–486.

  • Munos, B., Can open-source drug R&D repower pharmaceutical innovation? Clin. Pharmacol. Ther., 2010, 87(5), 534–536.

  • Kelkar, V. et al., Reinventing the CSIR: Report of the Committee to Assess and Evaluate the Outcomes of CSIR Activities, CSIR, Editor, Council of Scientific and Industrial Research (CSIR), New Delhi, 2004.

  • Vashisht, R. et al., Systems level mapping of metabolic complexity in Mycobacterium tuberculosis to identify high-value drug targets. J. Trans. Med., 2014, 12(1), 23.

  • Vashisht, R. and Brahmachari, S. K., Metformin as a potential combination therapy with existing front-line antibiotics for Tuberculosis. J. Trans. Med., 2015, 13(1), 83.

  • Kaur, D. et al., Data intensive genome level analysis for identifying novel, non-toxic drug targets for multi drug resistant Mycobacterium tuberculosis. Sci. Rep., 2017, 7.

  • OSDD, Open Source Drug Discovery; www.osdd.net

  • Santhosh, R. et al., Open access Mycobacterium tuberculosis clone repository: a community resource by OSDD members. Curr. Sci., 2013. 105(10), 1342–1345.

  • Mangal, M. et al., NPACT: naturally occurring plant-based anticancer compound-activity-target database. Nucl. Acids Res., 2012, 41(D1), D1124–D1129.

  • Metri, R. et al., SInCRe – structural interactome computational resource for Mycobacterium tuberculosis. Database, 2015, 2015, p. bav060.

  • Chandran, N. and Brahmachari, S. K., Technology, knowledge and markets: connecting the dots – electric rickshaw in India as a case study. J. Frugal Innov., 2015, 1(1), p. 3.

  • Bureau, P. I., India takes a Lead in TB Research in a Unique Mission Mode to End TB, New Delhi, 2016.


Abstract Views: 398

PDF Views: 131




  • A Decade of OSDD for TB:Role and Outcomes

Abstract Views: 398  |  PDF Views: 131

Authors

Nisha Chandran
CSIR-Institute of Genomics and Integrative Biology (IGIB), New Delhi 110 025, India
Samir K. Brahmachari
Academy of Scientific and Innovative Research (AcSIR), New Delhi 110 025, India

Abstract


In this article we estimate the economic benefit of open source drug discovery (OSDD) programme for its decade-long effort of developing newer and novel therapeutics for TB by streamlining the upstream research and development (R&D) of the drug discovery pipeline. The OSDD programme, presently subsumed into the India TB Research and Development Consortium (ITRDC) project led by ICMR, has opened up a novel method of asset utilization and capacity building at a negligible cost, leading to positive economic impact. The OSDD programme has also become an instrumental part of shaping the National Intellectual Property Rights (NIPR) Policy, 2016. This calls for a policy directive as programmes such as OSDD can be a powerful strategy in dealing with the excruciating disease burden of TB and other neglected diseases that countries such as India are facing.

Keywords


Drug Discovery, Economic Benefit, ITRDC, India NIPR, Open Source Drug Discovery, Tuberculosis.

References





DOI: https://doi.org/10.18520/cs%2Fv115%2Fi10%2F1858-1864